H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Theravance Biopharma (TBPH) to $27 from $20 and keeps a Buy rating on the shares. The firm sees upside in the shares as the company approaches the CYPRESS data, expected by the end of Q1. It views ampreloxetine’s development “as a case study in matching mechanism to the right indication, selecting the right patients.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- TBPH Earnings this Week: How Will it Perform?
- Largest borrow rate increases among liquid names
- Theravance Biopharma: Asymmetric Upside from Ampreloxetine on Top of a Cash-Flow-Positive Base Business Supports Buy Rating
- Theravance Biopharma management to meet with B. Riley
- Theravance Biopharma highlights cash-generation, YUPELRI growth, ampreloxetine